marcus
@mwl471
Followers
61
Following
4K
Media
206
Statuses
6K
Joined September 2013
“top priority for our Government” Labour’s top priority, everyone
I’m delighted that Alaa Abd El-Fattah has arrived in the UK and is with his family. Alaa’s case has been a top priority for our Government and I welcome President Sisi’s granting of this pardon. I pay tribute to Alaa’s family for their tireless determination to be reunited.
163
2K
10K
Autophagy-Driven Mitochondrial Inheritance Shapes CD8+ T Cell Fate, Division New findings could aid future development of more efficient therapeutic strategies in the context of regenerative medicine and aging @nanaborsa
#autophagy #celldivision #Tcells
https://t.co/PWY6gGVP01
genengnews.com
New findings could aid future development of more efficient therapeutic strategies in the context of regenerative medicine and aging.
1
4
7
Allergy Therapeutics, Scancell, IXICO, Ariana Resources - Small Cap Snapshot https://t.co/V6KKd8UAtJ
#Allergy #Peanut #Melanoma #Imaging #Neuroscience #Gold
0
1
1
$SCLP Scancell draws broker praise after fresh melanoma data and FDA progress https://t.co/dSX863Nz0f
@scancellpharma $SCP $SCNLF #SCLP #SCP #SCNLF
proactiveinvestors.co.uk
Panmure Liberum said Scancell Holdings PLC's (AIM:SCLP, OTC:SCNLF) latest clinical update has strengthened the case for its cancer vaccine programme,...
0
1
2
Further Ph II SCOPE #melanoma data at #ESMO-IO confirm durable iSCIB1+ response. #Immunobody construct chosen, target HLA pt pop defined & +ve FDA discussions re trial design (PFS endpoint): @scancellpharma is well positioned for next clinical steps #SCLP
trinitydelta.org
Investment research on Scancell. Scancell is a clinical-stage immuno-oncology specialist. The key value drivers are iSCIB1+, the lead ImmunoBody programme, and Modi-1, the lead Moditope programme....
0
1
1
Scancell’s iSCIB1+ shows 74% PFS in melanoma trial @scancellpharma
https://t.co/Wf2CCArvdJ
#Health #Pharmaceuticals #Biotechnology #Cancer #Melanoma
0
1
3
Scancell’s iSCIB1+ shows 74% PFS in melanoma trial @scancellpharma
https://t.co/Wf2CCArvdJ
#Health #Pharmaceuticals #Biotechnology #Cancer #Melanoma
0
1
1
The data will be shared today at the 67th @ASH_hematology Annual Meeting and Exposition. Read the press release here: https://t.co/s2sY9sQSib
#ASH2025 #DaretoBeam #BeamTeam
1
2
7
𝐅𝐫𝐨𝐦 𝐋𝐨𝐧𝐝𝐨𝐧: @CR_Horizons takes research from @CR_UK (and beyond) and invests in the translational work and companies that turn it into cures. Full video: https://t.co/P037T0dKfE
0
3
6
Accession Therapeutics doses first patient in new cancer immunotherapy trial
pharmafile.com
Biopharmaceutical company Accession Therapeutics has announced the dosing of the first patient in the phase 1 clinical trial of TROCEPT-01 (ATTR-01), its new
0
1
1
Key @scancellpharma value drivers lead #Immunobody asset iSCIB1+ (advanced #melanoma), on track to start a registrational trial, & #Moditope prog Modi-1 (solid tumours), plus its novel #GlyMab platform, are reviewed in our latest #SCLP $SCLP Outlook:
trinitydelta.org
Investment research on Scancell. Scancell is a clinical-stage immuno-oncology specialist. The key value drivers are iSCIB1+, the lead ImmunoBody programme, and Modi-1, the lead Moditope programme....
0
1
1
https://t.co/BkrYMCSlz0 Valuation of £382m ($477m), or 37p/share; Modi-1 CPI combo data due in Q425,Establishment of GlyMab Therapeutics,iSCIB1+ in combination with CPIs in advanced melanoma showing meaningfully improved outcomes across all key metrics (current sp 10p)
trinitydelta.org
Scancell | Outlook | 17 November 2025
0
0
0
https://t.co/2I7aoVUThE DNA Immunotherapy Shows Durable Response in Advanced Melanoma with Phil L’Huillier Scancell
0
0
1
The latest episode of the Molecular Therapy podcast is out now! This in-depth conversation focuses on an article recently published in @MolTherapy titled “Efficient in vivo generation of CAR T cells using a retargeted fourth-generation lentiviral vector.” 🎙️ Listen:
asgct.org
Editor-in-Chief of Molecular Therapy, Dr. Joseph Glorioso, is joined by Rachael Nimmo, PhD, and Kyriacos Mitrophanous, PhD, to discuss “Efficient in vivo…
0
1
6
'One person in the BBC newsroom is not left wing, and all the others have to find out who it is' My latest cartoon for tomorrow's @Telegraph Buy a print of my cartoons at https://t.co/ILFJjPmckx Original artwork from https://t.co/bVPAkgE34y
68
1K
5K
$SCLP Scancell hails promising melanoma trial results as plans accelerate for next stage https://t.co/3JHDugH6lb
@scancellpharma $SCP $SCNLF #SCLP #SCP #SCNLF
proactiveinvestors.co.uk
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) said on Friday that new data from its mid-stage cancer trial suggest its experimental therapy could outperform...
0
1
3
$SCLP Scancell hails promising melanoma trial results as plans accelerate for next stage https://t.co/bzSTJHVPVJ
@scancellpharma $SCP $SCNLF #SCLP #SCP #SCNLF
proactiveinvestors.co.uk
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) said on Friday that new data from its mid-stage cancer trial suggest its experimental therapy could outperform...
0
1
1
On Yervoy...
A powerful reminder of why we work in biotech, in good times and bad. From @normunity Founder Rachel Humphrey.❤️ See today's full discussion about persevering in biotech on BiotechTV here: https://t.co/5qtCAwBqxE
1
1
5
Have said it a lot lately, watch how brain shuttle technologies open up the neuro space to a new era. Congrats on the launch @Jack_O_Meara.
𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: Aerska launched in the UK today with $21M in financing to develop RNAi medicines for neurological conditions that are delivered to the brain via 'brain shuttle' technologies. CEO @Jack_O_Meara explains. Full video: https://t.co/edPHLpIpwa
8
6
39
Christians in Nigeria never carried out massacres, never dug tunnels, never fired rockets, never took hostages, never started a war. They are simply a peaceful community, half of Nigeria’s population, who only wanted to live in peace. Yet they are relentlessly attacked by Islamic
2K
29K
72K